This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Stocks making big moves yesterday: Helios, DraftKings, CACI, U.S. Physical Therapy, and Ulta

StockStory - StockStory - Wed May 13, 8:00AM CDT
HLIO

HLIO Cover Image

Check out the companies making headlines yesterday:

Helios (NYSE:HLIO): Motion control and electronic systems manufacturer Helios Technologies (NYSE:HLIO) rose by 12.5% on Tuesday after the company reported first-quarter 2026 results that exceeded analyst expectations and raised its full-year outlook. See our full article here.

Is now the time to buy Helios? Access our full analysis report here, it's free.

DraftKings (NASDAQ:DKNG): Fantasy sports and betting company DraftKings (NASDAQ:DKNG) rose by 2.2% on Tuesday after analysts at Truist Securities reiterated a Buy rating on the company's shares. See our full article here.

Is now the time to buy DraftKings? Access our full analysis report here, it's free.

CACI (NYSE:CACI): Defense, intelligence, and IT solutions provider CACI International (NYSE:CACI) rose by 3.5% on Tuesday after it secured a $113.8 million contract from the U.S. Navy. See our full article here.

Is now the time to buy CACI? Access our full analysis report here, it's free.

U.S. Physical Therapy (NYSE:USPH): Outpatient physical therapy provider U.S. Physical Therapy (NYSE:USPH) rose by 4.4% on Tuesday after the stock continued to rally as the company reported solid first-quarter 2026 results, highlighted by strong revenue growth and a confirmation of its full-year financial outlook. See our full article here.

Is now the time to buy U.S. Physical Therapy? Access our full analysis report here, it's free.

Ulta (NASDAQ:ULTA): Beauty, cosmetics, and personal care retailer Ulta Beauty (NASDAQ:ULTA) fell by 1.9% on Tuesday after April CPI hit 3.8%, the highest reading in nearly three years, confirming that tariffs and oil would show up in store prices. See our full article here.

Is now the time to buy Ulta? Access our full analysis report here, it's free.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).